Showing results (531-540 of 594) with videos related to
Sort By:
Pageof 60
The Journal of Clinical Investigation|December 1, 1976
The Sézary syndrome: a malignant proliferation of helper T cellsS Broder, R L Edelson, M A Lutzner, et al.Cancer Research|January 1, 1990
Immunomodulatory properties and toxicity of interleukin 2 in patients with cancerW J Urba, R G Steis, D L Longo, et al.Journal of Medical Genetics|December 10, 1997
Prenatal diagnosis of the fragile X syndrome: loss of mutation owing to a double recombinant or gene conversion event at the FMR1 locusM Losekoot, E Hoogendoorn, R Olmer, et al.Human Molecular Genetics|March 1, 1997
Molecular and phenotypic variation in patients with severe Hunter syndromeK M Timms, M L Bondeson, M A Ansari-Lari, et al.Journal of Clinical Microbiology|August 1, 1986
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infectionD K Wagner, B S Graham, P F Wright, et al.Human Molecular Genetics|April 1, 1993
Alternative splicing in the fragile X gene FMR1A J Verkerk, E de Graaff, K De Boulle, et al.The American Review of Respiratory Disease|September 1, 1989
Dynamic changes in soluble interleukin-2 receptor levels after lung or heart-lung transplantationE C Lawrence, V A Holland, J B Young, et al.Cell|November 24, 2001
Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndromeV Brown, P Jin, S Ceman, et al.Acta Crystallographica. Section C, Crystal Structure Communications|November 8, 2006
Dichloro(4,10-dimethyl-1,4,7,10-tetraazabicyclo[5.5.2]tetradecane)iron(III) hexafluorophosphateJames M McClain, Danny L Maples, Randall D Maples, et al.The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994
Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivityM M Foreman, R W Fuller, K Rasmussen, et al.Pageof 60